Nosocomial fungal infections: epidemiology, diagnosis, and treatment

References

• Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5: 26–34
   PubMed Web of Science ®Google Scholar
• Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20: 1526–1530
   PubMed Web of Science ®Google Scholar
• Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29 Suppl A: 19–24.
   PubMedGoogle Scholar
• Nucci M, Pulcheri W, Spector N, et al. Fungal infections in neutropenic patients. An 8-year prospective study. Rev Inst Med Trop Sao Paulo 1995; 37: 397–406
   PubMedGoogle Scholar
• Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis 2004; 39(Suppl. 1)S7–S10
   PubMedGoogle Scholar
• Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27: 1138–1147
   PubMed Web of Science ®Google Scholar
• Wajszczuk CP, Dummer JS, Ho M, et al. Fungal infections in liver transplant recipients. Transplantation 1985; 40: 347–353
   PubMed Web of Science ®Google Scholar
• Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319–1324
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917
   PubMed Web of Science ®Google Scholar
• Hibberd PL, Rubin RH. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 1994; 19(Suppl. 1)S33–40
   PubMedGoogle Scholar
• Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239–244
   PubMed Web of Science ®Google Scholar
• Rangel–Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29: 253–258
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309–317
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003; 22: 686–691
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103–1110
   PubMed Web of Science ®Google Scholar
• Kami M, Machida U, Okuzumi K, et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol 2002; 117: 40–46
   PubMed Web of Science ®Google Scholar
• Berenguer J, Buck M, Witebsky F, et al. Lysis–centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993; 17: 103–109
   PubMed Web of Science ®Google Scholar
• Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population–based active surveillance. Clin Infect Dis 1999; 29: 1164–1170
   PubMed Web of Science ®Google Scholar
• Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519–1527
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232–1239
   PubMed Web of Science ®Google Scholar
• Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414–421
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Zhanel GG, Klym KA, Hoban DJ, Kabani AM. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis 1977; 29: 5–9
   Google Scholar
• Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17: 504–508
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Oude Lashof AM. Epidemiology of opportunistic invasive mycoses. Eur J Med Res 2002; 7: 183–191
   PubMed Web of Science ®Google Scholar
• Pfaller MA. Epidemiology of candidiasis. J Hosp Infect 1995; 30(Suppl)329–38
   PubMedGoogle Scholar
• Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991; 13: 211–215
   PubMedGoogle Scholar
• Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002; 50: 56–65
   PubMed Web of Science ®Google Scholar
• Sendid B, Cotteau A, Francois N, et al. Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis 2006; 6: 80
   PubMed Web of Science ®Google Scholar
• Morgan J. Global trends in candidemia: review of reports from 1995–2005. Curr Infect Dis Rep 2005; 7: 429–439
   PubMedGoogle Scholar
• Albrecht SJ, Fishman NO, Kitchen J, et al. Reemergence of gram-negative health care-associated bloodstream infections. Arch Intern Med 2006; 166: 1289–1294
   PubMedGoogle Scholar
• Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21
   PubMed Web of Science ®Google Scholar
• Sandven P, Bevanger L, Digranes A, et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 2006; 44: 1977–1981
   PubMed Web of Science ®Google Scholar
• Luzzati R, Amalfitano G, Lazzarini L, et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur J Clin Microbiol Infect Dis 2000; 19: 602–607
   PubMed Web of Science ®Google Scholar
• Nolla–Salas J, Sitges–Serra A, Leon–Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997; 23: 23–30
   PubMed Web of Science ®Google Scholar
• Rennert G, Rennert HS, Pitlik S, Finkelstein R, Kitzes-Cohen R. Epidemiology of candidemia – a nationwide survey in Israel. Infection 2000; 28: 26–29
   PubMed Web of Science ®Google Scholar
• Wright WL, Wenzel RP. Nosocomial Candida. Epidemiology, transmission, and prevention. Infect Dis Clin North Am 1997; 11: 411–425
   PubMed Web of Science ®Google Scholar
• Alonso-Valle H, Acha O, Garcia-Palomo JD, et al. Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003; 22: 254–257
   PubMedGoogle Scholar
• Baran J, Jr, Muckatira B, Khatib R. Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand J Infect Dis 2001; 33: 137–139
   PubMedGoogle Scholar
• Borzotta AP, Beardsley K. Candida infections in critically ill trauma patients: a retrospective case-control study. Arch Surg 1999; 134: 657–664; discussion 664–665.
   PubMedGoogle Scholar
• Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989; 87: 614–620
   PubMed Web of Science ®Google Scholar
• Debusk CH, Daoud R, Thirumoorthi MC, Wilson FM, Khatib R. Candidemia: current epidemiologic characteristics and a long-term follow-up of the survivors. Scand J Infect Dis 1994; 26: 697–703
   PubMed Web of Science ®Google Scholar
• McKinnon PS, Goff DA, Kern JW, , et al Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg 2001; 136: 1401–1408; discussion 1409.
   PubMed Web of Science ®Google Scholar
• Charles PE, Doise JM, Quenot JP, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med 2003; 29: 2162–2169
   PubMed Web of Science ®Google Scholar
• Peman J, Canton E, Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005; 24: 23–30
   PubMed Web of Science ®Google Scholar
• Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2002; 43: 1829–1835
   Google Scholar
• Karabinis A, Hill C, Leclercq B, et al. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988; 26: 429–432
   PubMed Web of Science ®Google Scholar
• Martino P, Girmenia C, Micozzi A, et al. Fungemia in patients with leukemia. Am J Med Sci 1993; 306: 225–232
   PubMed Web of Science ®Google Scholar
• Pagano L, Antinori A, Ammassari A, et al. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. Eur J Haematol 1999; 63: 77–85
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309–316
   PubMed Web of Science ®Google Scholar
• Martino P, Girmenia C, Venditti M, et al. Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer 1989; 64: 2030–2034
   PubMed Web of Science ®Google Scholar
• Tran LT, Auger P, Marchand R, Carrier M, Pelletier C. Epidemiological study of Candida spp. colonization in cardiovascular surgical patients. Mycoses 1997; 40: 169–173
   PubMedGoogle Scholar
• Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus–positive individuals. J Clin Microbiol 2002; 40: 341–350
   PubMed Web of Science ®Google Scholar
• Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751–758
   PubMed Web of Science ®Google Scholar
• Voss A, Hollis RJ, Pfaller MA, Wenzel RP, Doebbeling BN. Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol 1994; 32: 975–980
   PubMed Web of Science ®Google Scholar
• Marco F, Lockhart SR, Pfaller MA, et al. Elucidating the origins of nosocomial infections with Candida albicans by DNA fingerprinting with the complex probe Ca3. J Clin Microbiol 1999; 37: 2817–2828
   PubMed Web of Science ®Google Scholar
• Klempp-Selb B, Rimek D, Kappe R. Karyotyping of Candida albicans and Candida glabrata from patients with Candida sepsis. Mycoses 2000; 43: 159–163
   PubMedGoogle Scholar
• Daniels W, Glover DD, Essmann M, Larsen B. Candidiasis during pregnancy may result from isogenic commensal strains. Infect Dis Obstet Gynecol 2001; 9: 65–73
   PubMedGoogle Scholar
• Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra–abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066–1072
   PubMed Web of Science ®Google Scholar
• Rotrosen D, Calderone RA, Edwards JE, Jr. Adherence of Candida species to host tissues and plastic surfaces. Rev Infect Dis 1986; 8: 73–85
   PubMedGoogle Scholar
• Douglas LJ. Adhesion of Candida species to epithelial surfaces. Crit Rev Microbiol 1987; 15: 27–43
   PubMed Web of Science ®Google Scholar
• Kiehn TE, Edwards FF, Armstrong D. The prevalence of yeasts in clinical specimens from cancer patients. Am J Clin Pathol 1980; 73: 518–521
   PubMedGoogle Scholar
• Marsh PK, Tally FP, Kellum J, Callow A, Gorbach SL. Candida infections in surgical patients. Ann Surg 1983; 198: 42–47
   PubMed Web of Science ®Google Scholar
• Safdar A, Chaturvedi V, Cross EW, et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001; 45: 2129–2133
   PubMed Web of Science ®Google Scholar
• Lehrer N, Segal E, Barr–Nea L. In vitro and in vivo adherence of Candida albicans to mucosal surfaces. Ann Microbiol (Paris) 1983; 134B: 293–306
   PubMedGoogle Scholar
• Ray TL, Digre KB, Payne CD. Adherence of Candida species to human epidermal corneocytes and buccal mucosal cells: correlation with cutaneous pathogenicity. J Invest Dermatol 1984; 83: 37–41
   PubMedGoogle Scholar
• Maraki S, Mouzas IA, Kontoyiannis DP, et al. Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by Candida species. Chemotherapy 2001; 47: 215–218
   PubMedGoogle Scholar
• Mavromanolakis E, Maraki S, Cranidis A, et al. The impact of norfloxacin, ciprofloxacin and ofloxacin on human gut colonization by Candida albicans. Scand J Infect Dis 2001; 33: 477–478
   PubMedGoogle Scholar
• Samonis G, Thomakos N, Liakakos T, et al. Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans. Chemotherapy 2001; 47: 350–353
   PubMed Web of Science ®Google Scholar
• Snelling CF, Ronald AR, Waters WR, et al. Comparison of silver sulfadiazine and gentamicin for topical prophylaxis against burn wound sepsis. Can Med Assoc J 1978; 119: 466–470
   PubMedGoogle Scholar
• Seelig MS. The role of antibiotics in the pathogenesis of Candida infections. Am J Med 1966; 40: 887–917
   PubMed Web of Science ®Google Scholar
• Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19: 319–324
   PubMed Web of Science ®Google Scholar
• Hung CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Nosocomial candidemia in a university hospital in Taiwan. J Formos Med Assoc 1996; 95: 19–28
   PubMedGoogle Scholar
• Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149: 2349–2353
   PubMed Web of Science ®Google Scholar
• Ekenna O, Sherertz RJ, Bingham H. Natural history of bloodstream infections in a burn patient population: the importance of candidemia. Am J Infect Control 1993; 21: 189–95
   PubMedGoogle Scholar
• Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531–1534
   PubMed Web of Science ®Google Scholar
• Krcmery V, Jr, Oravcova E, Spanik S, et al. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. J Antimicrob Chemother 1998; 41: 373–380
   PubMed Web of Science ®Google Scholar
• MacDonald L, Baker C, Chenoweth C. Risk factors for candidemia in a children's hospital. Clin Infect Dis 1998; 26: 642–645
   PubMed Web of Science ®Google Scholar
• Launay O, Lortholary O, Bouges–Michel C, et al. Candidemia: a nosocomial complication in adults with late-stage AIDS. Clin Infect Dis 1998; 26: 1134–1141
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Tacconelli E, de Gaetano Donati K, et al. Candidemia in HIV-infected subjects. Eur J Clin Microbiol Infect Dis 1999; 18: 478–483
   PubMed Web of Science ®Google Scholar
• Richards KE, Pierson CL, Bucciarelli L, Feller I. Monilial sepsis in the surgical patient. Surg Clin North Am 1972; 52: 1399–1406
   PubMed Web of Science ®Google Scholar
• Kralovicova K, Spanik S, Oravcova E, et al. Fungemia in cancer patients undergoing chemotherapy versus surgery: risk factors, etiology and outcome. Scand J Inf Dis 1997; 29: 301–304
   PubMed Web of Science ®Google Scholar
• Blijlevens NM, Donnelly JP, de Pauw BE. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 2002; 117: 259–264
   PubMedGoogle Scholar
• Ang BS, Telenti A, King B, Steckelberg JM, Wilson WR. Candidemia from a urinary tract source: microbiological aspects and clinical significance. Clin Infect Dis 1993; 17: 662–666
   PubMedGoogle Scholar
• Gross M, Winkler H, Pitlik S, Weinberger M. Unexpected candidemia complicating ureteroscopy and urinary stenting. Eur J Clin Microbiol Infect Dis 1998; 17: 583–586
   PubMedGoogle Scholar
• Sallah S, Wan JY, Nguyen NP, Vos P, Sigounas G. Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting: a follow-up study. Cancer 2001; 92: 1349–1353
   PubMed Web of Science ®Google Scholar
• Ramirez-Amador V, Silverman S, Jr, Mayer P, Tyler M, Quivey J. Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84: 149–153
   PubMed Web of Science ®Google Scholar
• Pappo I, Polacheck I, Zmora O, Feigin E, Freund HR. Altered gut barrier function to Candida during parenteral nutrition. Nutrition 1994; 10: 151–154
   PubMedGoogle Scholar
• Stone HH, Kolb LD, Currie CA, Geheber CE, Cuzzell JZ. Candida sepsis: pathogenesis and principles of treatments. Ann Surg 1974; 179: 697–711
   PubMed Web of Science ®Google Scholar
• Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. Clin Infect Dis 1996; 22(Suppl. 2)S73–88
   PubMed Web of Science ®Google Scholar
• Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet 1969; 1: 598–599
   PubMed Web of Science ®Google Scholar
• Eubanks PJ, de Virgilio C, Klein S, Bongard F. Candida sepsis in surgical patients. Am J Surg 1993; 166: 617–619; discussion 619–620.
   PubMed Web of Science ®Google Scholar
• Shirabe K, Takenaka K, Yamatomto K, et al. Impaired systemic immunity and frequent infection in patients with Candida antigen after hepatectomy. Hepatogastroenterology 1997; 44: 199–204
   PubMedGoogle Scholar
• Gaines JD, Remington JS. Disseminated candidiasis in the surgical patient. Surgery 1972; 72: 730–736
   PubMed Web of Science ®Google Scholar
• Bayer AS, Blumenkrantz MJ, Montgomerie JZ, et al. Candida peritonitis. Report of 22 cases and review of the English literature. Am J Med 1976; 61: 832–840
   PubMed Web of Science ®Google Scholar
• Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2(8677)1437–1440
   PubMedGoogle Scholar
• Michalopoulos A, Stavridis G, Geroulanos S. Severe sepsis in cardiac surgical patients. Eur J Surg 1998; 164: 217–222
   PubMedGoogle Scholar
• Antunes PE, Bernardo JE, Eugenio L, de Oliveira JF, Antunes MJ. Mediastinitis after aorto-coronary bypass surgery. Eur J Cardiothorac Surg 1997; 12: 443–449
   PubMed Web of Science ®Google Scholar
• Giamarellou H. Nosocomial cardiac infections. J Hosp Infect 2002; 50: 91–105
   PubMedGoogle Scholar
• Mestres CA, Chuquiure, JE, Claramonte X, , et al Long-term results after cardiac surgery in patients infected with the human immunodeficiency virus type-1 (HIV-1). Eur J Cardiothorac Surg 2003; 23: 1007–1016; discussion 1016.
   PubMedGoogle Scholar
• Verghese S, Mullasari A, Padmaja P, et al. Fungal endocarditis following cardiac surgery. Indian Heart J 1998; 50: 418–422
   PubMedGoogle Scholar
• DeGregorio MW, Lee WM, Ries CA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982; 50: 2780–2784
   PubMed Web of Science ®Google Scholar
• Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992; 14(Suppl. 1)S120–125
   Google Scholar
• Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238–245
   PubMed Web of Science ®Google Scholar
• Uzun O, Anaissie EJ. Predictors of outcome in cancer patients with candidemia. Ann Oncol 2000; 11: 1517–1521
   PubMedGoogle Scholar
• Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001; 32: 1713–1717
   PubMed Web of Science ®Google Scholar
• Heidenreich S, Kubis T, Schmidt M, Fegeler W. Glucocorticoid-induced alterations of monocyte defense mechanisms against Candida albicans. Cell Immunol 1994; 157: 320–327
   PubMed Web of Science ®Google Scholar
• Ziege SU, Geerdes–Fenge HF, Rau M, Buchwald U, Lode H. In vitro effects of interleukin-10, prednisolone, and GM–CSF on the non–specific immune function of human polymorphonuclear leucocytes and monocytes. Eur J Med Res 2000; 5: 369–374
   PubMedGoogle Scholar
• Haroon Parupia MF, Dhanireddy R. Association of postnatal dexamethasone use and fungal sepsis in the development of severe retinopathy of prematurity and progression to laser therapy in extremely low-birth-weight infants. J Perinatol 2001; 21: 242–247
   PubMedGoogle Scholar
• Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 2003; 101: 548–556
   PubMed Web of Science ®Google Scholar
• Powderly WG, Mayer KH, Perfect JR. Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retroviruses 1999; 15: 1405–1412
   PubMed Web of Science ®Google Scholar
• Brieland J, Essig D, Jackson C, et al. Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Inf Immun 2001; 69: 5046–5055
   PubMed Web of Science ®Google Scholar
• Stanley VC, Hurley R. The growth of Candida species in cultures of mouse peritoneal macrophages. J Pathol 1969; 97: 357–366
   PubMedGoogle Scholar
• Ibrahim AS, Spellberg BJ, Avanesian V, Fu Y, Edwards JEJ. The anti-Candida rAls1p-N vaccine is broadly active against disseminated candidiasis. Infect Immun 2006; 74: 3039–3041
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298–1302
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003; 41: 1440–1446
   PubMed Web of Science ®Google Scholar
• Colombo AL, Nucci M, Salomao R, et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999; 34: 281–286
   PubMed Web of Science ®Google Scholar
• Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22: 470–474
   PubMed Web of Science ®Google Scholar
• Cuenca–Estrella M, Rodriguez D, Almirante B, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002–2003. J Antimicrob Chemother 2005; 55: 194–199
   PubMed Web of Science ®Google Scholar
• Antoniadou A, Torres HA, Lewis RE, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003; 82: 309–321
   PubMed Web of Science ®Google Scholar
• Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001; 28: 873–878
   PubMed Web of Science ®Google Scholar
• St-Germain G, Laverdiere M, Pelletier R, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001; 39: 949–953
   PubMed Web of Science ®Google Scholar
• Chave JP, Durussel C, Glauser MP, Bille J. Asymptomatic oral yeast carriage in HIV-infected patients: frequency and fluconazole susceptibility profile. Clin Microbiol Infect 1996; 1: 249–252
   PubMedGoogle Scholar
• Hunter KD, Gibson J, Lockhart P, Pithie A, Bagg J. Fluconazole-resistant Candida species in the oral flora of fluconazole-exposed HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 558–564
   PubMed Web of Science ®Google Scholar
• Borst A, Raimer MT, Warnock DW, Morrison CJ, Arthington-Skaggs BA. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother 2005; 49: 783–787
   PubMed Web of Science ®Google Scholar
• Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005; 80: 868–871
   PubMed Web of Science ®Google Scholar
• Nawrot U, Nowicka J, Juszczak K, Gusin B. Susceptibility to antifungal agents of Candida species isolated from paediatric and adult patients with haematological diseases. Mycoses 2005; 48: 385–390
   PubMed Web of Science ®Google Scholar
• Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44: 529–535
   PubMed Web of Science ®Google Scholar
• Panackal AA, Gribskov JL, Staab JF, et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006; 44: 1740–1743
   PubMed Web of Science ®Google Scholar
• Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital–acquired Candida glabrata and Candida krusei fungemia: a case-control study. Antimicrob Agents Chemother 2005; 49: 4555–4560
   PubMed Web of Science ®Google Scholar
• Malani A, Hmoud J, Chiu L, et al. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005; 41: 975–981
   PubMed Web of Science ®Google Scholar
• Weinberger M, Leibovici L, Perez S, et al. Characteristics of candidaemia with Candida albicans compared with non-C. albicans Candida species and predictors of mortality. J Hosp Infect 2005; 61: 146–154
   PubMedGoogle Scholar
• Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995; 39: 1696–1699
   PubMed Web of Science ®Google Scholar
• Drago M, Scaltrito MM, Morace G. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis 2004; 23: 619–624
   PubMed Web of Science ®Google Scholar
• Safdar A, Armstrong D, Cross EW, Perlin DS. Prospective epidemiologic analysis of triazole-resistant nosocomial Candida glabrata isolated from patients at a comprehensive cancer center. Int J Infect Dis 2002; 6: 198–201
   PubMedGoogle Scholar
• Swinne D, Watelle M, Van der Flaes M, Nolard N. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-C. albicans bloodstream yeast isolates (CANARI study). Mycoses 2004; 47: 177–183
   PubMedGoogle Scholar
• Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161–189
   PubMed Web of Science ®Google Scholar
• Pai MP, Turpin RS, Garey KW. Association of fluconazole AUC/MIC and dose/MIC ratios with mortality in non-neutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51: 35–39
   PubMed Web of Science ®Google Scholar
• Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998; 42: 2645–2649
   PubMed Web of Science ®Google Scholar
• Krcmery V, Jr, Mrazova M, Kunova A, et al. Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution. Support Care Cancer 1999; 7: 428–431
   PubMed Web of Science ®Google Scholar
• Masala L, Luzzati R, Maccacaro L, et al. Nosocomial cluster of Candida guillermondii fungemia in surgical patients. Eur J Clin Microbiol Infect Dis 2003; 22: 686–688
   PubMedGoogle Scholar
• Fanello S, Bouchara JP, Jousset N, Delbos V, LeFlohic AM. Nosocomial Candida albicans acquisition in a geriatric unit: epidemiology and evidence for person–to–person transmission. J Hosp Infect 2001; 47: 46–52
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Houston A, et al. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis 1998; 310: 289–296
   Google Scholar
• Vazquez JA, Dembry LM, Sanchez V, et al. Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol 1998; 36: 421–426
   PubMed Web of Science ®Google Scholar
• Pertowski CA, Baron RC, Lasker BA, Werner SB, Jarvis WR. Nosocomial outbreak of Candida albicans sternal wound infections following cardiac surgery traced to a scrub nurse. J Infect Dis 1995; 172: 817–822
   PubMed Web of Science ®Google Scholar
• Sandt C, Sockalingum GD, Aubert D, et al. Use of Fourier-transform infrared spectroscopy for typing of Candida albicans strains isolated in intensive care units. J Clin Microbiol 2003; 41: 954–959
   PubMed Web of Science ®Google Scholar
• Stephan F, Bah MS, Desterke C, et al. Molecular diversity and routes of colonization of Candida albicans in a surgical intensive care unit, as studied using microsatellite markers. Clin Infect Dis 2002; 35: 1477–1483
   PubMedGoogle Scholar
• Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172–1177
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634–643
   PubMed Web of Science ®Google Scholar
• Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642–2645
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie EJ, Queiroz–Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98: 315–319
   PubMed Web of Science ®Google Scholar
• Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003; 37: 50–58
   PubMed Web of Science ®Google Scholar
• Lark RL, Chenoweth C, Saint S, et al. Four year prospective evaluation of nosocomial bacteremia: epidemiology, microbiology, and patient outcome. Diagn Microbiol Infect Dis 2000; 38: 131–140
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435–1442
   PubMed Web of Science ®Google Scholar
• Blau IW, Fauser AA. Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis. Mycoses 2000; 43: 325–332
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–1396
   PubMed Web of Science ®Google Scholar
• Mora–Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020–2029
   PubMed Web of Science ®Google Scholar
• Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25–31
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640–3645
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589–1596
   PubMed Web of Science ®Google Scholar
• Edwards JE, Jr, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43–59
   PubMed Web of Science ®Google Scholar
• Reboli A, Rotstein C, Pappas P, , et al Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis (C/IC). Abstract M-718. In: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005; Washington, DC: ASM; 2005.
   Google Scholar
• Ruhnke M, Kuse E, Chetchotisakd P, Arns Da Cunha C, Diekmann-Berndt H. Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. Abstract M-722c. In: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005; Washington, DC: 2005.
   Google Scholar
• Betts RF, Rotstein C, Talwar D, , et al Comparison of micafungin and caspofungin for candidemia or invasive candidiasis (IC). Abstract #M-1308a In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA; 2006.
   Google Scholar
• Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16: 337–345
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325–1330
   PubMed Web of Science ®Google Scholar
• Spellberg B, Filler SG, Edwards JE, Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244–251
   PubMed Web of Science ®Google Scholar
• Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005; 49: 3616–3623
   PubMed Web of Science ®Google Scholar
• Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221–1228
   PubMed Web of Science ®Google Scholar
• Van Burik J, Weisdorf D. Infections in recipients of hematopoeitic stem cell transplantation. Principles and Practice of Infectious Diseases6th ed., GL Mandell, JE Bennett, R Dolin. Elsevier, Philadelphia, PA 2005; 3486–3501
   Google Scholar
• Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002; 51: 288–296
   PubMed Web of Science ®Google Scholar
• Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998; 37: 173–80
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK, Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192–198
   PubMed Web of Science ®Google Scholar
• Ribrag V, Dreyfus F, Venot A, et al. Prognostic factors of invasive pulmonary aspergillosis in leukemic patients. Leuk Lymphoma 1993; 10: 317–321
   PubMed Web of Science ®Google Scholar
• Iwen PC, Reed EC, Armitage JO, et al. Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplants. Infect Control Hosp Epidemiol 1993; 14: 131–139
   PubMedGoogle Scholar
• Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol 1991; 9: 77–84
   PubMed Web of Science ®Google Scholar
• Mullins J, Harvey R, Seaton A. Sources and incidence of airborne Aspergillus fumigatus (Fres). Clin Allergy 1976; 6: 209–217
   PubMedGoogle Scholar
• Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment – rethinking our approach to prevention. Clin Infect Dis 2001; 33: 1549–1552
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002; 34: 780–789
   PubMed Web of Science ®Google Scholar
• Loo VG, Bertrand C, Dixon C, et al. Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. Infect Control Hosp Epidemiol 1996; 17: 360–364
   PubMed Web of Science ®Google Scholar
• Klimowski LL, Rotstein C, Cummings KM. Incidence of nosocomial aspergillosis in patients with leukemia over a twenty-year period. Infect Control Hosp Epidemiol 1989; 10: 299–305
   PubMedGoogle Scholar
• Hopkins CC, Weber DJ, Rubin RH. Invasive Aspergillus infection: possible non-ward common source within the hospital environment. J Hosp Infect 1989; 13: 19–25
   PubMedGoogle Scholar
• Perraud M, Piens MA, Nicoloyannis N, et al. Invasive nosocomial pulmonary aspergillosis: risk factors and hospital building works. Epidemiol Infect 1987; 99: 407–412
   PubMed Web of Science ®Google Scholar
• Arnow PM, Andersen RL, Mainous PD, Smith EJ. Pumonary aspergillosis during hospital renovation. Am Rev Respir Dis 1978; 118: 49–53
   PubMed Web of Science ®Google Scholar
• Cooper EE, O'Reilly MA, Guest DI, Dharmage SC. Influence of building construction work on Aspergillus infection in a hospital setting. Infect Control Hosp Epidemiol 2003; 24: 472–476
   PubMed Web of Science ®Google Scholar
• Pegues CF, Daar ES, Murthy AR. The epidemiology of invasive pulmonary aspergillosis at a large teaching hospital. Infect Control Hosp Epidemiol 2001; 22: 370–374
   PubMedGoogle Scholar
• Raad I, Hanna H, Osting C, et al. Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction. Infect Control Hosp Epidemiol 2002; 23: 41–43
   PubMedGoogle Scholar
• Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66: 257–262
   PubMed Web of Science ®Google Scholar
• Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987; 83: 709–718
   PubMed Web of Science ®Google Scholar
• Alberti C, Bouakline A, Ribaud P, et al. Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. J Hosp Infect 2001; 48: 198–206
   PubMed Web of Science ®Google Scholar
• Barnes RA, Rogers TR. Control of an outbreak of nosocomial aspergillosis by laminar air-flow isolation. J Hosp Infect 1989; 14: 89–94
   PubMedGoogle Scholar
• Eckmanns T, Ruden H, Gastmeier P. The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis 2006; 193: 1408–1418
   PubMed Web of Science ®Google Scholar
• Bodey GP, Freireich EJ. Influence of high-efficiency particulate air filtration on mortality and fungal infection: a rebuttal. J Infect Dis 2006; 194: 1621–1622
   PubMedGoogle Scholar
• Brakhage AA. Systemic fungal infections caused by Aspergillus species: epidemiology, infection process and virulence determinants. Curr Drug Targets 2005; 6: 875–886
   PubMed Web of Science ®Google Scholar
• Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343–2345
   PubMed Web of Science ®Google Scholar
• Lass–Florl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42: 497–502
   PubMed Web of Science ®Google Scholar
• Hachem RY, Kontoyiannis DP, Boktour MR, et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 2004; 101: 1594–1600
   PubMed Web of Science ®Google Scholar
• Patterson JE, Peters J, Calhoon JH, et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000; 2: 22–28
   PubMedGoogle Scholar
• Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest 1998; 114: 251–262
   PubMed Web of Science ®Google Scholar
• Wallace JM, Lim R, Browdy BL, et al. Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest 1998; 114: 131–137
   PubMed Web of Science ®Google Scholar
• Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459–1466
   PubMed Web of Science ®Google Scholar
• Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44–69
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366
   PubMed Web of Science ®Google Scholar
• Duthie R, Denning DW. Aspergillus fungemia: report of two cases and review. Clin Infect Dis 1995; 20: 598–605
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Habicht J, Matt P, et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant 1999; 24: 1195–1199
   PubMed Web of Science ®Google Scholar
• Yu VL, Muder RR, Poorsattar A. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med 1986; 81: 249–254
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 696–709
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349–357
   PubMed Web of Science ®Google Scholar
• Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417–1427
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Klont RR, Warris A, Op den Camp HJ, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 2004; 363: 325–327
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Ruegebrink D, Klont RR, et al. Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol 2005; 43: 3925–3931
   PubMed Web of Science ®Google Scholar
• Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349: 2366–2367
   PubMed Web of Science ®Google Scholar
• Adam O, Auperin A, Wilquin F, et al. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917–920
   PubMed Web of Science ®Google Scholar
• Aubry A, Porcher R, Bottero J, et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006; 44: 389–394
   PubMed Web of Science ®Google Scholar
• Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5: 609–622
   PubMed Web of Science ®Google Scholar
• Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis 2006; 8: 128–139
   PubMed Web of Science ®Google Scholar
• Hebart H, Loffler J, Meisner C, et al. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000; 181: 1713–1719
   PubMed Web of Science ®Google Scholar
• Horger M, Hebart H, Einsele H, et al. Initial CT manifestations of invasive pulmonary aspergillosis in 45 non-HIV immunocompromised patients: association with patient outcome?. Eur J Radiol 2005; 55: 437–444
   PubMed Web of Science ®Google Scholar
• Brodoefel H, Vogel M, Hebart H, et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. AJR Am J Roentgenol 2006; 187: 404–413
   PubMed Web of Science ®Google Scholar
• Lee YR, Choi YW, Lee KJ, et al. CT halo sign: the spectrum of pulmonary diseases. Br J Radiol 2005; 78: 862–865
   PubMed Web of Science ®Google Scholar
• Horger M, Einsele H, Schumacher U, et al. Invasive pulmonary aspergillosis: frequency and meaning of the ‘hypodense sign’ on unenhanced CT. Br J Radiol 2005; 78: 697–703
   PubMed Web of Science ®Google Scholar
• Hauggaard A, Ellis M, Ekelund L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol 2002; 43: 292–298
   PubMed Web of Science ®Google Scholar
• Kami M, Kishi Y, Hamaki T, et al. The value of the chest computed tomography halo sign in the diagnosis of invasive pulmonary aspergillosis. An autopsy-based retrospective study of 48 patients. Mycoses 2002; 45: 287–294
   PubMed Web of Science ®Google Scholar
• Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253–259
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366
   PubMed Web of Science ®Google Scholar
• Martino R, Cortes M, Subira M, et al. Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leuk Lymphoma 2005; 46: 1429–1435
   PubMed Web of Science ®Google Scholar
• Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28(Suppl. B)73–82
   PubMed Web of Science ®Google Scholar
• Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36: 372–379
   PubMed Web of Science ®Google Scholar
• Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001; 40: 511–520
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
   PubMed Web of Science ®Google Scholar
• Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003; 109: 111–118
   PubMed Web of Science ®Google Scholar
• Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33: e83–90
   PubMed Web of Science ®Google Scholar
• Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994; 97: 135–144
   PubMed Web of Science ®Google Scholar
• Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 2323(3 Pt 2)607–614
   Google Scholar
• Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad, II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5: 775–785.
   Google Scholar
• Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56: 745–755
   PubMed Web of Science ®Google Scholar
• Steinbach WJ. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Curr Drug Targets Infect Disord 2005; 5: 203–210
   PubMedGoogle Scholar
• Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797–802
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320–326
   PubMed Web of Science ®Google Scholar
• Spellberg B, Edwards J, Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556–569
   PubMed Web of Science ®Google Scholar
• Hotchi M, Okada M, Nasu T. Present state of fungal infections in autopsy cases in Japan. Am J Clin Pathol 1980; 74: 410–416
   PubMed Web of Science ®Google Scholar
• Tietz HJ, Brehmer D, Janisch W, Martin H. [Incidence of endomycoses in the autopsy material of the Berlin Charite Hospital]. Mycoses 1998; 41(Suppl. 2)81–5
   PubMedGoogle Scholar
• Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: 1732–1738
   PubMed Web of Science ®Google Scholar
• Nussbaum ES, Hall WA. Rhinocerebral mucormycosis: changing patterns of disease. Surg Neurol 1994; 41: 152–156
   PubMed Web of Science ®Google Scholar
• Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24: 307–312
   PubMed Web of Science ®Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952
   PubMed Web of Science ®Google Scholar
• Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236–301
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653
   PubMed Web of Science ®Google Scholar
• Kwon-Chung KJ, Bennett JE. Mucormycosis. Philadelphia: Lea & Febiger 1992: 524–559.
   Google Scholar
• Ibrahim AS, J. E. J. Edwards, Filler, S. G. Zygomycosis. In: Clinical mycology. Dismukes WE, Pappas PG, and Sobel JD. 2003. Oxford University Press. p. 241–251.
   Google Scholar
• Cohen-Abbo A, Bozeman PM, Patrick CC. Cunninghamella infections: review and report of two cases of Cunninghamella pneumonia in immunocompromised children. Clin Infect Dis 1993; 17: 173–177
   PubMed Web of Science ®Google Scholar
• Kwon-Chung KJ, Young RC, Orlando M. Pulmonary mucormycosis caused by Cunninghamella elegans in a patient with chronic myelogenous leukemia. Am J Clin Path 1975; 64: 544–548
   PubMed Web of Science ®Google Scholar
• Kontoyianis DP, Vartivarian S, Anaissie EJ, et al. Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. Clin Infect Dis 1994; 18: 925–928
   PubMed Web of Science ®Google Scholar
• Ventura GJ, Kantarjian HM, Anaissie E, Hopfer RL, Fainstein V. Pneumonia with Cunninghamella species in patients with hematologic malignancies. A case report and review of the literature. Cancer 1986; 58: 1534–1536
   PubMed Web of Science ®Google Scholar
• Bearer EA, Nelson PR, Chowers MY, Davis CE. Cutaneous zygomycosis caused by Saksenaea vasiformis in a diabetic patient. J Clin Microbiol 1994; 32: 1823–1824
   PubMedGoogle Scholar
• Lye GR, Wood G, Nimmo G. Subcutaneous zygomycosis due to Saksenaea vasiformis: rapid isolate identification using a modified sporulation technique. Pathology 1996; 28: 364–365
   PubMed Web of Science ®Google Scholar
• Kemna ME, Neri RC, Ali R, Salkin IF. Cokeromyces recurvatus, a mucoraceous zygomycete rarely isolated in clinical laboratories. J Clin Microbiol 1994; 32: 843–845
   PubMedGoogle Scholar
• Kamalam A, Thambiah AS. Cutaneous infection by Syncephalastrum. Sabouraudia 1980; 18: 19–20
   PubMedGoogle Scholar
• Rickerts V, Bohme A, Just–Nubling G. [Risk factor for invasive zygomycosis in patients with hematologic malignancies]. Mycoses 2002; 45(Suppl. 1)27–30
   PubMedGoogle Scholar
• Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the in a tertiary-care cancer center. Clin Infect Dis 1990s; 2000(30)851–856
   Google Scholar
• Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39: 588–590
   PubMed Web of Science ®Google Scholar
• Gartenberg G, Bottone EJ, Keusch GT, Weitzman I. Hospital-acquired mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous tissue: epidemiology, mycology and treatment. N Engl J Med 1978; 299: 1115–1118
   PubMed Web of Science ®Google Scholar
• Petrikkos G, Skiada A, Sambatakou H, et al. Mucormycosis: ten-year experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis 2003; 22: 753–756
   PubMed Web of Science ®Google Scholar
• Adam RD, Hunter G, DiTomasso J, Comerci G, Jr. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis 1994; 19: 67–76.
   PubMedGoogle Scholar
• Baraia J, Munoz P, Bernaldo de Quiros JC, Bouza E. Cutaneous mucormycosis in a heart transplant patient associated with a peripheral catheter. Eur J Clin Microbiol Infect Dis 1995; 14: 813–815
   PubMed Web of Science ®Google Scholar
• Khardori N, Hayat S, Rolston K, Bodey GP. Cutaneous Rhizopus and Aspergillus infections in five patients with cancer. Arch Dermatol 1989; 125: 952–956
   PubMedGoogle Scholar
• Leong KW, Crowley B, White B, et al. Cutaneous mucormycosis due to Absidia corymbifera occurring after bone marrow transplantation. Bone Marrow Transplant 1997; 19: 513–515
   PubMedGoogle Scholar
• Harper JJ, Coulter C, Lye GR, Nimmo GR. Rhizopus and tongue depressors. Lancet 1996; 348: 1250
   PubMedGoogle Scholar
• Maravi–Poma E, Rodriguez–Tudela JL, de Jalon JG, et al. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med 2004; 30: 724–728
   PubMedGoogle Scholar
• Holzel H, Macqueen S, MacDonald A, et al. Rhizopus microsporus in wooden tongue depressors: a major threat or minor inconvenience?. J Hosp Infect 1998; 38: 113–118
   PubMedGoogle Scholar
• Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584–587
   PubMed Web of Science ®Google Scholar
• Pavie J, Lafaurie M, Lacroix C, et al. Successful treatment of pulmonary mucormycosis in an allogenic bone-marrow transplant recipient with combined medical and surgical therapy. Scand J Infect Dis 2004; 36: 767–769
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743–746
   PubMed Web of Science ®Google Scholar
• Ide L, Buysschaert I, Demuynck H, et al. Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole?. Clin Microbiol Infect 2004; 10: 862–863
   PubMed Web of Science ®Google Scholar
• Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005; 40: e35–7
   PubMed Web of Science ®Google Scholar
• Morrison VA, McGlave PB. Mucormycosis in the BMT population. Bone Marrow Transplant 1993; 11: 383–388
   PubMed Web of Science ®Google Scholar
• Alsuwaida K. Primary cutaneous mucormycosis complicating the use of adhesive tape to secure the endotracheal tube. Can J Anaesth 2002; 49: 880–882
   PubMedGoogle Scholar
• Kerr OA, Bong C, Wallis C, Tidman MJ. Primary cutaneous mucormycosis masquerading as pyoderma gangrenosum. Br J Dermatol 2004; 150: 1212–1213
   PubMedGoogle Scholar
• Quinio D, Karam A, Leroy JP, et al. Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med Mycol 2004; 42: 177–180
   PubMed Web of Science ®Google Scholar
• Mead JH, Lupton GP, Dillavou CL, Odom RB. Cutaneous Rhizopus infection. Occurrence as a postoperative complication associated with an elasticized adhesive dressing. JAMA 1979; 242: 272–274
   PubMedGoogle Scholar
• Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41: 60–66
   PubMed Web of Science ®Google Scholar
• Nithyanandam S, Jacob MS, Battu RR, et al. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol 2003; 51: 231–236
   PubMedGoogle Scholar
• Mori T, Egashira M, Kawamata N, et al. [Zygomycosis: two case reports and review of reported cases in the literature in Japan]. Nippon Ishinkin Gakkai Zasshi 2003; 44: 163–179
   PubMedGoogle Scholar
• Sugar AM. Agents of Mucormycosis and Related Species. In: Principles and practice of infectious diseases, 6th edition. Mandell Gl, Bennet JE, and Dolin R. Philadelphia: Elsevier 2005: 2979.
   Google Scholar
• Ericsson M, Anniko M, Gustafsson H, et al. A case of chronic progressive rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery. Clin Infect Dis 1993; 16: 585–586
   PubMedGoogle Scholar
• Cagatay AA, Oncu SS, Calangu SS, et al. Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report. BMC Infect Dis 2001; 1: 22
   PubMedGoogle Scholar
• Weng DE, Wilson WH, Little R, Walsh TJ. Successful medical management of isolated renal zygomycosis: case report and review. Clin Infect Dis 1998; 26: 601–605
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Avanessian V, Spellberg B, Edwards JE, Jr. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003; 47: 3343–3344
   PubMedGoogle Scholar
• Spellberg B, Fu Y, Edwards JE, Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830–832
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Klein S, Lee H, , et al. Efficacy of amphotericin B lipid complex in murine mucormycosis. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada. 2000.
   Google Scholar
• Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182: 274–282
   PubMed Web of Science ®Google Scholar
• Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases?. Leuk Lymphoma 2004; 45: 1351–1360
   PubMed Web of Science ®Google Scholar
• Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581–1582
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2000; 46: 1032–1037
   Google Scholar
• van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61–5
   PubMed Web of Science ®Google Scholar
• Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002; 46: 2310–2312
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003; 47: 3647–3650
   PubMed Web of Science ®Google Scholar
• Espinel–Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK–0991 (L–743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950–2956
   PubMed Web of Science ®Google Scholar
• Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L–743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41: 1835–1836
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49: 721–727
   PubMed Web of Science ®Google Scholar
• Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994; 45: 667–671
   PubMed Web of Science ®Google Scholar
• Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91: 1979–1986
   PubMed Web of Science ®Google Scholar
• de Locht M, Boelaert JR, Schneider YJ. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 1994; 47: 1843–1850
   PubMedGoogle Scholar
• Ibrahim AS, Edwards JE, Jr, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006; 58: 1070–1073
   PubMed Web of Science ®Google Scholar
• Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 2005; 18: 289–298
   PubMed Web of Science ®Google Scholar
• Reed C, Ibrahim AS, Edwards JE, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006; 50: 3968–3969.
   Google Scholar
• Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope 1997; 107: 855–862
   PubMed Web of Science ®Google Scholar
• Khor BS, Lee MH, Leu HS, Liu JW. Rhinocerebral mucormycosis in Taiwan. J Microbiol Immunol Infect 2003; 36: 266–269
   PubMedGoogle Scholar
• Tedder M, Spratt JA, Anstadt MP, et al. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57: 1044–1050
   PubMed Web of Science ®Google Scholar
• Reid VJ, Solnik DL, Daskalakis T, Sheka KP. Management of bronchovascular mucormycosis in a diabetic: a surgical success. Ann Thorac Surg 2004; 78: 1449–1451
   PubMedGoogle Scholar
• Asai K, Suzuki K, Takahashi T, et al. Pulmonary resection with chest wall removal and reconstruction for invasive pulmonary mucormycosis during antileukemia chemotherapy. Jpn J Thorac Cardiovasc Surg 2003; 51: 163–166
   PubMedGoogle Scholar
• Morrison VA, Haake RJ, Weisdorf DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994; 96: 497–503
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237–1242
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001; 33: 1871–1878
   PubMed Web of Science ®Google Scholar
• Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10(Suppl. 1)67–75
   PubMed Web of Science ®Google Scholar
• Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001; 32: 1237–1240
   PubMed Web of Science ®Google Scholar
• Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood 1997; 90: 999–1008
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35: 909–920
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10(Suppl. 1)48–66
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419–4431
   PubMed Web of Science ®Google Scholar
• Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398–1403
   PubMed Web of Science ®Google Scholar
• Abzug MJ, Walsh TJ. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004; 23: 769–773
   PubMed Web of Science ®Google Scholar
• Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40: 89–99
   PubMed Web of Science ®Google Scholar
• Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45: 2151–2153
   PubMed Web of Science ®Google Scholar
• Gosbell IB, Toumasatos V, Yong J, et al. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003; 46: 233–236
   PubMed Web of Science ®Google Scholar
• Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22: 111–113
   PubMed Web of Science ®Google Scholar
• Whyte M, Irving H, O'Regan P, et al. Disseminated Scedosporium prolificans infection and survival of a child with acute lymphoblastic leukemia. Pediatr Infect Dis J 2005; 24: 375–377
   PubMedGoogle Scholar
• Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23: 805–812
   PubMed Web of Science ®Google Scholar
• Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005; 45: 1373–1382
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49: 1331–1336
   PubMed Web of Science ®Google Scholar
• Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739–745
   PubMed Web of Science ®Google Scholar